New Modern Approach to Cancer: Biobran Workshop in Krakow 2017

1. 5th International Biobran Workshop New Modern Way to Approach Cancer 9 – 11 June 2017 Krakow Poland Speaker: Serge Jurasunas N.D., M.D. (Hom) Professor of Naturopathic Oncology www.sergejurasunas.com

2. Up to now the conventional treatments of surgery, chemotherapy and radiotherapy have reached a maximum plateau of EFFICACY and we can EXPECT only little PROGRESS or NONE in the future. Professor Dominique Belpomme, Oncologist author of the book “Guerir du cancer ou s’en Proteger”. France

3. Serge Jurasunas N.D.M.D. (Hom) Pioneer in Natural Medicine and Naturopathic Oncology Practitioner – Researcher – Author – 50 years of practice Author of 7 books 2017 New book: Health and Disease Begin in the Colon - Featuring Professor Serge Jurasunas’ Natural Medicine www.sergejurasunas.com Blog: http:/naturopathiconcology.blogspot.com

4. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis Presentation • The problem of modern Oncology • New Hallmarks of Cancer • Apoptosis, Immunotherapy, Angiogenesis • Biobran Mgn3 • Liquid Cartilage Extract (LCE) • Curcumin • Case examples

5. Where are We Today with Cancer ? Despite the progress in Oncology and some benefit in the gold standard of palliative therapy, surgery and radiation, conventional treatment has not achieved the hope and expectation to cure cancer. In metastasic cancer, Oncology is not better than 30 years ago. There has been no significant change in the survival rate.

6. Problems of Conventional Oncology → Multidrug Resistance → Radiotherapy resistance → Chemotherapy is very toxic and may be fatal to patients → Many Anticancer drugs show no efficacy → Metastasis cancer is incurable and responsible for 90% of deaths

7. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis A strong need for new less toxic and more efficient approaches to cancer treatment. Three main Hallmarks responsable for tumor growth, metastasis condition and tumor invasion: 1 – Apoptosis 2 – Angiogenesis 3 – Immune Surveillance “Hallmarks of Cancer. The Next Generation.” Hanahan D., Weinberg R.A. (Cell journal 2000)

8. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis The p53 Tumor Suppresssor Protein The p53 tumor supressor protein is activated when DNA is damaged. The p53 gene is called the “Guardian Angel of the Genome” • p53 protein activates genes for proteins that: • Preventcellsentering S phase • Repair DNA • Cause apoptosis (if DNA isirreparable DNA repair Apoptosis Cellcannotenter S phase

9. p53 Transcriptionally Controls BCL-2 and BAX to Mediate Apoptosis

10. p53 Mutations in Cancer ■ p53 is the most commonly mutated gene harbored in more than half of all cancers. ■ p53 inactivated or mutated appears necessary to develop many forms of cancer. ■ Restoring p53 WT function or activation may offer a therapeutic benefit. Read: Serge Jurasunas - The p53 Tumor Supressor Gene Understanding p53 Based Anticancer Therapies Utilizing Dietary Agents. Townsend Letter – August/Sept 2015

11. Growth of Xenograft Tumors Tumors with intact p53 gene regressed during the treatment, whereas the tumors with defective p53 genes continued to grow.

13. Video from a Researcher at the University of Singapore (From My Science Work) Reactivating the Immune System Against Cancer: A Role for Natural Compounds A number of recent articles published in various countries have shown that reactivating the immune system to treat cancer is now attracting oncology.

15. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis Biobran/Mgn3 The BREAKTHROUGH in Immuno-Oncology Two decades of studies show that Biobran/Mgn3 a natural compound made from modified rice bran is a potent immunomodulator of NK cells, our most important line of defense against cancer including T-cells, B-cells and global immune system function.

16. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis Biobran a Biological Response Modifier Biobran is a hemicellulose complex, a dietary fiber containing Arabinoxylan as a major component which is produced from modified rice bran and enzymatically treated with an extract from mycellia shitake mushroom. Before the process Arabinoxylan itself has no immunostimulating activity until the long polyssacharides molecules are broken up into smaller components.

17. Digestion, Absorption and Function of Biobran Dietary fibers are eliminated by the intestine but Biobran is absorbed in the small intestine practically undigested entering into the blood to become a nutritional food that activates N.K.cells and optimizes immune function when taken orally.

18. Biobran increases the Curve of NK cells If you prescribe 2g of Biobran to volunteers then you can see a curve of NK cells increasing about 60% after two weeks. But if you continue, you can achieve up to 200 even 300% or more NK cell number and activity. NK cells are here but not activated to release their toxic enzymes (perforin) through the membrane of cancer cells. Ghoneum M. “Enhancement of Human natural killer cells activity by modified arabinoxylan from rice bran. (Mgn3) Int. Immunotherapy 1998. XIV.89-99

20. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis • Cancer patients on chemotherapy have a depressed NK cell activity attributed to a decrease or absence of perforin and granzymes (1). • Mgn3 Biobran studies have shown that the treatment causes an increase in the granular content (perforin and granzymes) of NK cells. • It also results in an increased NK cell binding capacity to cancer cells. (1) Culler S.P. Brunet M., Martin S.J. – Ganzymes in cancer and immunity – Cell Death Differ. 2010.17-616-623

21. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis NK Immunorestoration of Cancer Patients by Biobran/Mgn3 • Figure 3: Cytocentrifuge preparation of two K562 tumor cells undergoing destruction by one NK cell. NK cellswereactivatedby MGN-3 • First step in the process represented by the binding of an NK cell to tumor cells. (Giema, X740) • Preparationshowingone tumor cellisdead. (Giema, X740) • Preparation showing both tumor cells are dead while an NK cell in between is still alive. (Giema, X740) • Cytocentrifuge preparation showing NK cell has detached itself from the dead tumor cells. (Giema, X740)

22. NK Cells Killing Cancer Cells

23. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis New modern way to approach cancer Strategic immunotherapy, apoptosis and angiogenesis Significant Synergism

24. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis Biobran Enhances the Effect of Chemotherapy Leading to Effective Treatment at Low Dosage with Less Toxic Effect and More Results

25. Some of Our Clients Have Been Taking Biobran on Long-Term Follow Up from 2-4-7 Years Without Toxicity

26. Biobran Improves Cancer Patient Survival Rates 205 cancer patients with progressive and metastatic disease stage (III-IV) after conventional treatment with surgery and adjuvant chemotherapy. The Biobran group received 2 gr of Biobran per day, the control group did not receive anything. Biobran Group Control Group 2 year survival 52/96 (54.2% 19/63 (33.9%) NK activity 20% 17/40 (42.5%) 2/16 (12.5%) 20% - 40% 10/35 (51.4%) 7/25 (28.0%) 40% 17/21 (81.0% 10/15 (66%) There are a significant differences compared to control group. P<0.01 P>0.05 . 52 of the patients in Biobran group survive 2 years. If patients have higher than 40% activity of the NK cells prior to go into study, they have a very high survival rate compared to the control group. Takahata K. – Abstract 3rd Annual meeting of the Japanese Society for complementary Medicine – Treatment, 2000.

27. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis A New Approach to Cancer – Antiangiogenic Therapy One promising new approach to Cancer Therapy is the use of drugs that inhibit Tumor Growth by interfering with the Angiogenic mechanism that shuts off tumor blood vessels. This is a non-toxic and selective therapy for Tumors.

28. The Effects of Liquid Cartilage Extract (L.C.E.) as an Angiogenic Inhibitor Shark cartilage is an avascular tissue that contains components able to stop the development of blood vessels needed for tumor growth. Shark is a particularly suitable source, since its skeleton is enterely formed by cartilage and its antiangiogenetic activity is 100,000 times that of mammalian cartilage. L.C.E is a concentrated hydrosoluble extract of liquid cartilage that contains biologically active mucopolysaccharides and proteins with strong antiangiogenic properties (1). L.C.E. may simultaneously target many different aspects of the angiogenic cascade to prevent the tumor from making new blood vessels and to destroy existing ones. In vitro L.C.E. Interferes with the VEGF binding and signaling to VEGF receptors, that tumors need to attract and build new blood vessels, thus inhibit migration of endothelial cells.

29. Cancers that Have Successfuly Responded to L.C.E. Thousands of patients have received L.C.E. This includes a variety of different cancer types mostly solid tumors but also non solid tumors. Prostate Breast Lung Kidney Lymphoma Glioma Results of animal studies of the efect of L.C.E. show a significant decrease in the number of lung nodules when used alone or in combination with cisplatin. L.C.E decreases bone metastasis in mice. These studies confirm with our own cancer cases, which we treat with lung nodules, especially those with bone metastasis. Non-operable tumors also respond well to L.C.E. together with chemotherapy regímen. I have had some isolated cases of breast cancer with no surgery and chemotherapy where the tumor was eliminated as well as the bone metastasis. Our patients have taken L.C.E. for a long-term period without toxicity.

30. The Effects of the Liquid Cartilage Extract (L.C.E.) as an Angiogenic Inhibitor • L.C.E. is available in 30ml concentrate vials (frozen liquid) or less concentrated in a non frozen vial both taken orally and shown to be bioavailable (2) and non-toxic in long term administration (3) compared to antiangiogenic drugs such as Avastin. • Lee A., and Langer R. – Shark Cartilage contains inhibitors of angiogenesis – Science 1983, 221-1185-1187 • Bilodeau D – A liquid extract with antiangiogenic and blood modulating activities, for the support of first line cancer treatment. 1st International Conference of the Society of Integrative Oncology. Poster nº36-NY 2004-Nov 17.19 • Berbari P., Thibodeau ª, Germain L., Saint-Cyr, M. Gaudieau P., El-Khouti S., Dupont E., Garrel DR. Oral Bioavailability of a Liquid Cartilage Extract: A Human Clinical Trial – J. Surg Research 1999-87-108-113.

31. Liquid Cartilage Extract Multiple Activities

33. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis Read my conferences on Cancer and Angiogenesis:. “Angiogenesis and Cancer – A Novel Approach” “Liquid Cartilage Extract as a Natural Nutritional Adjuvant for Conventional Therapies” 4th European Congress of Anti-Aging Medicine Oct.17-19-2008, Paris, France (online or at: www.sergejurasunas.com) 8th Congress for Nutri Phytotherapy March 2007, Brussels, Belgium

34. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis CURCUMIN – A Potent Anticancer Agent (Yellow ingredient derived from curcuma longa.l one of the most extensively investigated phytochemical compounds with ANTICANCER properties. (1) (1) Anticancer potential of curcuma. An old spice with new targets. Bharat B. Aggarwal Ph.D. University of Texas M.D. Anderson Cancer Center. Houston. TX.USA

35. Effects of Curcumin on the Interaction with Multiple Cell Signaling Proteins, Cancer and Chemotherapy

36. Human Melanoma Cell Line SK-MEL-37 Cells have been Treated with 15uM and 20uM of Curcumin for 24 hours: (B and D) Entering into Apoptosis. (A and C Untreated Cells). These cells have demonstrated to be resistant to doxorubicin, cisplatin in culture but sensitive to curcumin treatment. Curcumin potentializes the effectiveness of chemotherapy in a variety of cancers including breast, ovarian, colon and pancreatic and could become a promising tool. Marcella Lemos Carneiro – Morphological alterations and Go/G1 cell cycle arrest induced by curcumin in human SK-MEL-37 melanoma cells. Braz.arch.Biol. Technol.Vol.53 n.2.Curitiba.April.2010

37. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis Curcumin Increases the Sensitivity of Drug Treatment in Breast, Ovarian, Cervical, Pancreas and Colon Cancer • 5 Fu • Taxol • Pactitaxel • Cisplatin • Adramycin • Daunorubicin Koo J.Y. et al, 2002, VBS et al. 2003, Chan M.M., 2003, Chuang S.E. et al, 2002

38. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis A Study in Breast Cancer (Bayet-Robert and Collegues 2010) Oral curcumin and docetaxel administered to INOPERABLE breast cancer patients with advanced tumors and metastasis, became OPERABLE after the combination therapy. Patients had LOWERED tumor MARKERS and V.E.G.F. levels indicating REDUCED cancer cell SURVIVAL and ANGIOGENESIS, tumor SIZE and inflammation. (1) (1) Serge Jurasunas – Complementary Approach to Breast Cancer. A Case with Multiple Liver Metastasis is Free from Disease. Townsend Letter August/September 2015.

39. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis • Synergetic Effect of Biobran MGn3 and Curcumin in Cancer Treatment with Chemotherapy • - Faster reduction and/or elimination of secondary nodules in cancer recurrence. • Significant reduction of large tumors when taken together with chemotherapy. • Advanced cancers with multiple metastasis (Liver, lung, etc.), having received poor prognosis with a combination of chemotherapy, has resulted in prolongation of lifespan (6-8 years) with maintenance, along with an improved quality of life (QOL).

40. Curcumin Preparation (Lecifarma Lab – Portugal) Brand name: Curcumino Complex Presentation: Sachets of 100mg of liqid curcumin Developed for high absortion and bioavaibility Tests conducted at the Faculty of Pharmacy – University of Lisbon - Portugal +66% +115%

42. New Modern Way to Approach Cancer Strategic Immunotherapy, Apoptosis and Angiogenesis Protocol for Cancer Patients Biobran 1 sachet of 1mg 3 times per day, 20 minutes after a meal. L.C.E. (Comitris) 1 ampoule of 14ml sublingual to be kept 5 minutes in the mouth before swallowing. Curcumin 1 sachet of 1500 mg liquid diluted in water to take 3 times per day between meals. Additionaly as support to nutritional need, detoxification, boosting mitochondria function and activating ATP energy. Enzyme Yeast Cells (Zell-oxygen). Anticancer diet, cocktails of fresh vegetable juices.

43. A Few Interesting Case Histories • We Don’t Cure All the Cancers but… • Many cases after 25-30 years are alive and doing well. • Several have had a 10 year extension. • Several advanced cases have improved their quality of life with a life spent up to 7 years , including prostate cancer, multiple myeloma, breast cancer, and pancreatic cancer. • Unfortunately many cases come in too late that end up fatal from excess chemotherapy. • -Overall our treatments have demonstrated efficacy, help the patient by reducing toxic effects, improve chemotherapy effectiveness, quality of life and increase life expectancy.

44. Patient Male – 73 years old – Prostate Cancer Clinical story: Adenocarcinoma of the Prostate – Gleason 7 (3+4) - Advanced case – No Surgery or Chemotherapy/Radiation. 10/11/2005 – Bad physical condition – metastasis to bone skeleton – PSA 354 nl/ml Treatment – L.C.E. (Comitris) – Immunomodulator (Biobran) 3g per day 12/01/2006 - PSA 53.6 nl/ml - After 3 months PSA 1.4 nl/ml After 5 months elimination of almost all the bone metastasis.

45. Patient M – 81 years old – Recurrence of Colon Cancer - Liver Metastasis 1st Test: 9/3/2011 2nd Test: 11/8/2011 p53 Gene Expression p53 Gene Expression Reference range: 10-50 units/µl of plasma 1.180 units/ml of plasma Not detectable p53 Protein Level normal p53 Protein Level n normal Reference range: 0,33 units/µl of plasma Not detectable Not detectable p53 Protein Level mutated p53 Protein Level mutated Not detectable 10.88 units/µl of plasma Reference range: 10 units BCL2 Gene Expression BCL2 Gene Expression Apoptosis 340 units/µl of plasma Not detectable Reference range: 10-100 units BAX Gene Expression BAX Gene Expression 2 pools of resistance Not detectable 409 units/ml of plasma Reference range: 10 units Survivin Gene Expression Survivin Gene Expression 129 units/µl of plasma Not detectable Reference range: 10-50 units P21 Gene Expression P21 Gene Expression Not detectable Not detectable

46. Advanced Gastric Cancer - Results of Blood Analysis F.41 years – Asympthomatic Prime Lesions 18 cm – Secondary Lesions 8 cm Lesionof 30,1 mm Lesionof 48,7 mm Lesionof 18 cm July 2015 April 2015 July 2015 April 2015 Combination of chemotherapy with our complementary treatment that targets apoptosis, angiogenesis, immune activity – Anticancer Diet

47. Advanced Gastric Cancer - Result of Blood Analysis 1st Test: 28/04/2015 2nd Test: 26/06/2015 After the applied therapy p53 Gene Expression p53 Gene Expression Reference range: 10-50 units/µl of plasma 223 units/µl of plasma 58 units/µl of plasma p53 Protein Level normal p53 Protein Level n normal Reference range: 0,10 – 1,00 units/µl of plasma 1 unit/µl of plasma 4 units/µl of plasma p53 Protein Level mutated p53 Protein Level mutated Not detectable 35,4 units/µl of plasma Tumor Marker 2 – Pyruvate Kinase TM2.PK Tumor Marker 2 – Pyruvate Kinase TM2.PK Reference range: 5 - 15 units 23,8 units/µl of plasma 72,4 units/µl of plasma Comment: We significantly increased about 4 times the expression of p53 gene and increased only to a certain extent normal p53 protein. We reversed the production of mutant protein to normal wild type. TM2.PK activity decreased to an almost normal range.

48. Advanced Gastric Cancer - Photo taken on May, 2017

49. Breast Cancer with Multiple Metastasis to Liver Complete case published in Townsend Letter August/Sept 2014 or www.sergejurasunas.com Patient female, 44 years old diagnosed in October 2011 with a stage III left breast cancer, with dissemination of about 30 lesions to the liver; up to 1,5cm size for many localized in the left lobe, and segment III and IV of the right lobe. Breast tumor was about 3.5cm with inflammation spread to neighboring tissues; many swollen lymph nodes were diagnosed on the left part of the neck. Chemotherapy was suggested before surgery to reduce the tumor and the inflammation. January 2012 – The patient came into our clinic suffering from adverse side effects having had very little response from chemotherapy. She felt tired, nausea, loss of appetite, anxiety. We had taken 3 different tests: Live Blood Analysis, Oxidative Dried Blood Test and Molecular Markers Testing. These tests showed very high BCL2 activity, low BAX gene activity and especially very high VEGF levels showing activated angiogenesis in the solid tumor. Treatment – L.C.E., Biobran MGN-3, Curcumin and Anticancer Diet After 2 months of treatment the inflammation was almost gone, in the same way as the swallowed ganglions and reduced tumor. Surgery was done followed by chemotherapy and our treatment. In 2003 a new scan showed total elimination of the 30 liver nodules and complete remission. In 2017 the patient is still in remission but still comes in regularly for our check up exams.

50. Breast Cancer with Multiple Metastasis to the Liver A Complementary Approach to Breast Cancer: A Case with Multiple Liver Metastasis is Free from Disease Complete Report – Townsend Letter Magazine – August/Sept 2014